Modality
Radioligand
MOA
CAR-T CD19
Target
AuroraA
Pathway
PI3K/AKT
Migraine
Development Pipeline
Preclinical
Aug 2024
→ Mar 2030
PreclinicalCurrent
NCT07636880
1,352 pts·Migraine
2024-08→2030-03·Recruiting
1,352 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-113.9y awayInterim· Migraine
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Recruit…
Catalysts
Interim
2030-03-11 · 3.9y away
Migraine
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07636880 | Preclinical | Migraine | Recruiting | 1352 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA |